BCG
IBB icon

Bravias Capital Group’s iShares Biotechnology ETF IBB Stock Holding History

Bravias Capital Group’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$562K Buy
2,956
+608
+26% +$105K 0.33% 50
2026
Q1 		$396K Buy
2,348
+206
+10% +$35.2K 0.26% 58
2025
Q4 		$362K Buy
2,142
+1
+0% +$162 0.22% 75
2025
Q3 		$309K Buy
2,141
+51
+2% +$6.96K 0.21% 81
2025
Q2 		$264K Buy
2,090
+195
+10% +$23.9K 0.19% 81
2025
Q1 		$242K Buy
1,895
+161
+9% +$21.8K 0.2% 73
2024
Q4 		$240K Buy
+1,734
New +$244K 0.2% 84

Other funds holding IBB

Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
WA
WestEnd Advisors Charlotte, North Carolina $4.49B AUM 19.44% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
AFG
Albion Financial Group Salt Lake City, Utah $1.73B AUM 20.99% 1-Year Est. Return
GIC
Generali Investments CEE Prague, Czech Republic $2.11B AUM 25.53% 1-Year Est. Return
IHL
Investment House LLC Redondo Beach, California $2.21B AUM 39.6% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return
AP
Appleton Partners Boston, Massachusetts $1.63B AUM 38.57% 1-Year Est. Return
FMI
Factory Mutual Insurance Waltham, Massachusetts $10.6B AUM 34.1% 1-Year Est. Return

Bravias Capital Group's IBB Position: Q2 2026 in Review

Bravias Capital Group increased its iShares Biotechnology ETF (IBB) stake by 26% in Q2 2026, buying an estimated $105K and bringing the position to 2,956 shares worth $562K. The position accounts for 0.33% of the portfolio, ranked #50.

Bravias Capital Group first reported a position in IBB in Q4 2024 and has held it in 7 quarters since. 421 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • Bravias Capital Group held 2,956 shares of iShares Biotechnology ETF worth $562K as of Q2 2026.
  • Bravias Capital Group bought 608 iShares Biotechnology ETF shares in Q2 2026, an estimated $105K.
  • iShares Biotechnology ETF made up 0.33% of Bravias Capital Group's portfolio in Q2 2026, its #50 holding.
  • Bravias Capital Group first reported a position in iShares Biotechnology ETF in Q4 2024 and has held it in 7 quarters since.
  • 421 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Bravias Capital Group's 13F filing for Q2 2026, filed 30 Jul 2026.